Treatment of experimental allergic encephalomyelitis in rabbits with alpha-fetoprotein.
We studied the ability of alpha-fetoprotein (AFP) to suppress experimental allergic encephalomyelitis (EAE) in rabbits. Animals were treated with daily injections of 50 micrograms of AFP following the onset of neurological signs. Clinical status, anti-myelin basic protein (MBP) antibody titers, and histopathological changes in the CNS were determined. Treatment with AFP significantly improved the clinical scores of the affected rabbits and inhibited the binding of anti-MBP antibodies to MBP in vitro. However, there was no significant difference in the titers of anti-MBP antibody, and no amelioration of histopathological changes between treated and control animals. We conclude that AFP is effective in improving the clinical status of animals with EAE, even after the appearance of clinical signs.
T
T
Brenner
S
S
Evron
D
D
Soffer
O
O
Abramsky
D000818:Animals; D001323:Autoantibodies / Q000032:analysis; D002490:Central Nervous System / Q000473:pathology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D004676:Myelin Basic Protein / Q000276:immunology; D011817:Rabbits; D000509:alpha-Fetoproteins / Q000627:therapeutic use*
D001323:Autoantibodies; D004676:Myelin Basic Protein; D000509:alpha-Fetoproteins